Merck (MRK) Amortizatization of Intangibles (2020 - 2026)
Merck's (MRK) quarterly Amortizatization of Intangibles came in at $984.0 million in Q2 2026, up 63.73% year-over-year from $601.0 million in Q2 2025, and up 5.69% quarter-over-quarter from $931.0 million in Q1 2026.
Analysis
Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Merck (MRK) has reported Amortizatization of Intangibles for 7 consecutive years, with $984.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Amortizatization of Intangibles rose 63.73% year-over-year to $984.0 million in Q2 2026; TTM through Jun 2026 was $3.5 billion, a 40.1% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 16.62% from the prior year.
- Amortizatization of Intangibles was $984.0 million for Q2 2026 at Merck, up from $931.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $984.0 million in Q2 2026 and troughed at $460.0 million in Q3 2022.
- A 5-year average of $624.0 million and a median of $599.0 million in 2025 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles dropped 22.32% in 2023 and surged 63.73% in 2026, its largest moves.
- Over 5 years, Amortizatization of Intangibles stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then soared by 46.1% to $675.0 million in 2024, then jumped by 44.15% to $973.0 million in 2025, then climbed by 1.13% to $984.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $984.0 million (Q2 2026), $931.0 million (Q1 2026), and $973.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 4.33 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 984.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Sep 30, 2023 | 562.00 Mn |
| Jun 30, 2023 | 477.00 Mn |
| Mar 31, 2023 | 543.00 Mn |
| Dec 31, 2022 | 462.00 Mn |
| Sep 30, 2022 | 460.00 Mn |
| Jun 30, 2022 | 463.00 Mn |
| Mar 31, 2022 | 699.00 Mn |
| Dec 31, 2021 | 405.00 Mn |
| Sep 30, 2021 | 360.00 Mn |